Determination of the cyclic depsipeptide FK228 in human and mouse plasma by liquid chromatography with mass-spectrometric detection

被引:14
作者
Chen, Xiaohong [1 ]
Gardner, Erin R. [2 ]
Figg, William D. [1 ]
机构
[1] NCI, Clin Pharmacol Res Core, Bethesda, MD 20892 USA
[2] NCI, SAIC Frederick Inc, Clin Pharmacol Program, Frederick, MD 21702 USA
来源
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES | 2008年 / 865卷 / 1-2期
关键词
depsipeptide; human plasma; mouse plasma; LC/MS;
D O I
10.1016/j.jchromb.2008.02.015
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
An analytical method was developed and validated for the quantitative determination of the cyclic depsipeptide FK228 (romidepsin, formerly FR901228; NSC 630176), a histone deacetylase inhibitor, in human and mouse plasma. Calibration curves were linear in the concentration range of 2-1000 ng/mL. Sample pretreatment involved a liquid-liquid extraction of 0.1 mL aliquots of plasma with ethyl acetate. FK228 and the internal standard, harmine, were separated on a Zorbax SB C18 column (75 mm x 2.1 mm, 3.5 mu m), using a mobile phase composed of methanol and 0.2% formic acid. The column eluent was monitored by mass spectrometry with electrospray ionization. Accuracy and precision of four concentrations of quality control samples ranged from 101.5 to 106.4% and 0.7 to 3.5% in human plasma and 93.6 to 100.6% and 0.6 to 6.5%, in mouse plasma, respectively. This method represents a significant improvement over our previously published analytical assay for this agent, decreasing the sample volume requirements, increasing the accuracy and precision (through addition of a suitable internal standard), expanding the analytical range and validating in additional biological matrices. The developed method was applied to study the pharmacokinetics of FK228 in over 1000 clinical and preclinical samples. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:153 / 158
页数:6
相关论文
共 10 条
  • [1] [Anonymous], 2001, Guidance for industry, bioanalytical method validation
  • [2] Determination of the cyclic depsipeptide FK228, a histone deacetylase inhibitor, by liquid chromatography-mass spectrometry
    Hwang, K
    Piekarz, RL
    Bates, SE
    Figg, WD
    Sparreboom, A
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 809 (01): : 81 - 86
  • [3] Determination of midazolam in human plasma by liquid chromatography with mass-spectrometric detection
    Lepper, ER
    Hicks, JK
    Verweij, J
    Zhai, SP
    Figg, WD
    Sparreboom, A
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2004, 806 (02): : 305 - 310
  • [4] Marshall John L, 2002, J Exp Ther Oncol, V2, P325, DOI 10.1046/j.1359-4117.2002.01039.x
  • [5] Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma
    Piekarz, Richard L.
    Frye, A. Robin
    Wright, John J.
    Steinberg, Seth M.
    Liewehr, David J.
    Rosing, Douglas R.
    Sachdev, Vandana
    Fojo, Tito
    Bates, Susan E.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (12) : 3762 - 3773
  • [6] Sandor V, 2002, CLIN CANCER RES, V8, P718
  • [7] FR901228, A NOVEL ANTITUMOR BICYCLIC DEPSIPEPTIDE PRODUCED BY CHROMOBACTERIUM-VIOLACEUM NO-968 .2. STRUCTURE DETERMINATION
    SHIGEMATSU, N
    UEDA, H
    TAKASE, S
    TANAKA, H
    YAMAMOTO, K
    TADA, T
    [J]. JOURNAL OF ANTIBIOTICS, 1994, 47 (03) : 311 - 314
  • [8] UEDA H, 1994, J ANTIBIOT, V47, P301
  • [9] UEDA H, 1994, J ANTIBIOT, V47, P315
  • [10] ACTION OF FR901228, A NOVEL ANTITUMOR BICYCLIC DEPSIPEPTIDE PRODUCED BY CHROMOBACTERIUM-VIOLACEUM NO-968, ON HA-RAS TRANSFORMED NIH3T3 CELLS
    UEDA, H
    NAKAJIMA, H
    HORI, Y
    GOTO, T
    OKUHARA, M
    [J]. BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY, 1994, 58 (09) : 1579 - 1583